Acumen Pharmaceuticals (ABOS) Non-Current Assets (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Non-Current Assets of $535000.0 for Q1 2026, down 7.92% sequentially from $581000.0 in Q4 2025, and down 98.92% YoY from $49.5 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Non-Current Assets (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Non-Current Assets for 6 years, with the latest figure at $535000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 98.92% year-over-year to $535000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.7 million (down 81.9% YoY) and the FY2025 annual result came in at $581000.0, down 99.04% from the prior year.
- Non-Current Assets declined to $535000.0 in Q1 2026 per ABOS's latest filing, from $581000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $67.8 million in Q3 2023 and troughed at $535000.0 in Q1 2026.
- A 5-year average of $31.8 million and a median of $27.9 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets surged 9526.85% in 2023, then sank 99.04% in 2025.
- Over 5 years, Non-Current Assets stood at $16.3 million in 2022, then soared by 290.64% to $63.5 million in 2023, then decreased by 4.45% to $60.7 million in 2024, then plunged by 99.04% to $581000.0 in 2025, then dropped by 7.92% to $535000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $535000.0, $581000.0, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Acumen Pharmaceuticals | 233.37 Mn | 233.37 Mn | - | 494,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 494,000.00 |
| Mar 31, 2026 | 535,000.00 |
| Dec 31, 2025 | 581,000.00 |
| Sep 30, 2025 | 10.07 Mn |
| Jun 30, 2025 | 23.49 Mn |
| Mar 31, 2025 | 49.53 Mn |
| Dec 31, 2024 | 60.69 Mn |
| Sep 30, 2024 | 59.34 Mn |
| Jun 30, 2024 | 22.00 Mn |
| Mar 31, 2024 | 45.14 Mn |
| Dec 31, 2023 | 63.51 Mn |
| Sep 30, 2023 | 67.77 Mn |
| Jun 30, 2023 | 27.87 Mn |
| Mar 31, 2023 | 43.83 Mn |
| Dec 31, 2022 | 16.26 Mn |
| Sep 30, 2022 | 704,000.00 |
| Jun 30, 2022 | 20.63 Mn |
| Mar 31, 2022 | 27.99 Mn |
| Dec 31, 2021 | 31.67 Mn |
| Sep 30, 2021 | 29.94 Mn |